Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation

Taylor and Francis Group, Expert Opinion on Drug Safety, 2(15), p. 249-264, 2016

Journal article published in 2015 by Daisuke Yabe

, Yutaka Seino

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving forbidden

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by